Clinical Trial Update: An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults [Phase 2, Phase 3]

View source ↗

Summary

Adaptive Phase II/III study evaluating NaBen as add-on therapy to clozapine for residual symptoms in adults with refractory schizophrenia; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Clozapine (Clozapine)
• NaBen

Snippet

Sponsor: SyneuRx International (Taiwan) Corp | Conditions: Refractory Schizophrenia | Phase 2, Phase 3 | Status: RECRUITING